Researchers at University Hospitals' Harrington Discovery Institute in Cleveland say they have uncovered a new cellular choke point that might one day help outmaneuver cancers that stop responding to targeted drugs. The team reports that proteins inside the Golgi apparatus - the cell's shipping hub - help ferry growth-factor receptors to the cell surface, where they fire up tumor growth. Cut off that delivery route, and those receptors lose some of their punch. For now, the finding is a lab bench story, but it hints at fresh targets for lung, breast and colorectal cancers that have learned to dodge current treatments.
What the study showed
In work published May 19 in the journal Science Signaling, the team zeroed in on a previously overlooked set of Golgi proteins that tune receptor tyrosine kinase signaling. Led by Kyle Starost and colleagues, the study shows that tweaking these Golgi components in human cell models dials down activation of oncogenic receptors and the downstream pathways they control. That pattern suggests future drugs that disrupt Golgi machinery could work alongside, not instead of, medicines that hit the receptors directly.
Golgi proteins that matter
The spotlight landed on the Golgi phosphoprotein GOLPH3 and its partner MYO18A. Together, they help route major growth-factor receptors, including EGFR and HER2, to the cell surface, where they can drive cancer proliferation. According to University Hospitals, disrupting GOLPH3 or MYO18A in experimental models reduced receptor phosphorylation and tamped down the downstream signaling that fuels tumor growth. The mechanism offers a concrete explanation for why tumors with extra copies of GOLPH3 often behave more aggressively and shrug off therapy.
How they tested it
The researchers combined broad, unbiased screens of cell signaling with genetic knockdowns in human cancer cell models, then backed up those findings by analyzing human tumor samples, as reported by Cleveland.com. Across several tumor types, blocking the GOLPH3-MYO18A trafficking pair lowered activation of key oncogenic pathways. It is a strong signal, but still preclinical: the group notes that animal studies, followed by careful safety work, will be needed before anyone talks about trying this approach in patients.
Why it could change therapy
“Discoveries in fundamental biology are the fuel that enables advances in medicine,” said Seth J. Field, the study's senior author, in a statement carried by University Hospitals. Harrington Discovery Institute plans to push this basic insight along the translational pipeline, aiming to develop drug candidates that could be paired with receptor-blocking therapies to tackle resistance from two sides. The scientists are careful to stress that moving from a clever lab trick to a safe, approved cancer medicine will take many years of testing and refinement.
Harrington's role and next steps
The Harrington Discovery Institute, which focuses on steering academic discoveries toward real-world treatments, will oversee early drug-development work on targets such as GOLPH3 and MYO18A, according to the institute's release. EurekAlert notes that Harrington already backs dozens of programs designed to shepherd promising candidates toward clinical trials. Near-term priorities include proving that these Golgi targets matter in animal models and hunting for small molecules or biologic drugs that can safely interfere with Golgi-directed trafficking.
Bottom line
The study adds another piece to the growing picture of how cancer hijacks the cell's internal shipping lanes to keep growth signals jammed in the "on" position. It also highlights a nontraditional weak spot that drug developers may be eager to explore. For patients and clinicians in Cleveland, the work is an encouraging sign that the local translational pipeline is humming, even if any new treatment built on this strategy is still years - and many experiments - away.
